BioMarin Pharmaceutical Inc. Revenue 2008–2025
BioMarin Pharmaceutical Inc. reported $3.22B of revenue for fiscal 2025. That was 12.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +73.1%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $3.22B | +12.9% |
| FY 2024 | $2.85B | +18.0% |
| FY 2023 | $2.42B | +15.4% |
| FY 2022 | $2.10B | +13.5% |
| FY 2021 | $1.85B | -0.8% |
| FY 2020 | $1.86B | +9.2% |
| FY 2019 | $1.70B | +14.3% |
| FY 2018 | $1.49B | +13.5% |
| FY 2017 | $1.31B | +17.6% |
| FY 2016 | $1.12B | +25.5% |
| FY 2015 | $889.89M | +18.8% |
| FY 2014 | $749.28M | +36.6% |
| FY 2013 | $548.49M | +9.5% |
| FY 2012 | $500.72M | +13.5% |
| FY 2011 | $441.36M | +17.3% |
| FY 2010 | $376.27M | +15.9% |
| FY 2009 | $324.66M | +9.5% |
| FY 2008 | $296.49M | — |
Source: BioMarin Pharmaceutical Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BMRN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
BioMarin Pharmaceutical Inc. reported $3.22B of revenue for fiscal 2025. That was 12.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +73.1%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for BioMarin Pharmaceutical Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBioMarin Pharmaceutical Inc. — frequently asked questions
What is BioMarin Pharmaceutical Inc.'s revenue?
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $3.22B for fiscal year 2025, per its SEC filings.
How has BioMarin Pharmaceutical Inc.'s revenue changed over time?
Between fiscal 2008 and 2025, BMRN's revenue grew at roughly 15.1% per year (compound annual rate), from $296.49M to $3.22B.
Where does this data come from?
Figures are computed from BioMarin Pharmaceutical Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.